SEC Comment Letter 0000000000-26-003759 to ELITE PHARMACEUTICALS INC /NV/ (ELTP)

ELITE PHARMACEUTICALS INC /NV/
Date: April 14, 2026 · CIK: 0001053369 · Accession: 0000000000-26-003759

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 001-15697

Date

April 14, 2026

Author

Division of

Form

UPLOAD

Company

ELITE PHARMACEUTICALS INC /NV/

Letter

Re: Elite Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended March 31, 2025 Filed June 30, 2025 File No. 001-15697 Dear Carter Ward:

April 14, 2026

Carter Ward Chief Financial Officer Elite Pharmaceuticals, Inc. 165 Ludlow Avenue Northvale, New Jersey 07647

We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences

Show Raw Text

<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
                                                          April 14, 2026

Carter Ward
Chief Financial Officer
Elite Pharmaceuticals, Inc.
165 Ludlow Avenue
Northvale, New Jersey 07647

       Re: Elite Pharmaceuticals, Inc.
           Form 10-K for the Fiscal Year Ended March 31, 2025
           Filed June 30, 2025
           File No. 001-15697
Dear Carter Ward:

       We have completed our review of your filing. We remind you that the
company and its
management are responsible for the accuracy and adequacy of their disclosures,
notwithstanding
any review, comments, action or absence of action by the staff.

                                                          Sincerely,

                                                          Division of
Corporation Finance
                                                          Office of Life
Sciences
</TEXT>
</DOCUMENT>

SecProbe.io